Reduced CSF neurotensin concentration in drug-free schizophrenic patients

Leif H. Lindström, Erik Widerlöv, Garth Bisette, Charles Nemeroff

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The concentration of the tridecapeptide neurotensin was measured in CSF from 76 drug-free schizophrenic patients and 45 healthy controls. A highly significant difference was found between the two groups with lower concentration of neurotensin-like immunoreactivity in schizophrenic patients. Normalization of the lower concentrations was obtained in the same patients during ongoing neuroleptic treatment. The neurotensin concentrations in CSF was unrelated to sex, age, duration of the disorder or to previous neuroleptic treatment. Neurotensin levels did not differ between patients with or without a family history. A significant correlation was found between low neurotensin concentrations and decreased motor activity. No significant relationship was seen between the increment in CSF concentrations of neurotensin and clinical improvement during neuroleptic treatment. No significant correlation between CSF concentrations of neurotensin and HVA or 5-HIAA, major metabolites of dopamine and serotonin, respectively, could be demonstrated. However, in a limited number of the schizophrenic patients in this population, a significant correlation was seen between neurotensin and the noradrenaline metabolite MOPEG. The data support the hypothesis that certain schizophrenic patients may have a compromised CNS neurotensin system which might increase vulnerability for this disorder.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalSchizophrenia Research
Volume1
Issue number1
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Neurotensin
Pharmaceutical Preparations
Antipsychotic Agents
Methoxyhydroxyphenylglycol
Hydroxyindoleacetic Acid
Dopamine
Serotonin
Norepinephrine
Motor Activity
Therapeutics

Keywords

  • (Schizophrenia)
  • Cerebrospinal fluid
  • Comprehensive Psychopathological Rating Scale
  • Monoamine
  • Neurotensin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Reduced CSF neurotensin concentration in drug-free schizophrenic patients. / Lindström, Leif H.; Widerlöv, Erik; Bisette, Garth; Nemeroff, Charles.

In: Schizophrenia Research, Vol. 1, No. 1, 01.01.1988, p. 55-59.

Research output: Contribution to journalArticle

Lindström, Leif H. ; Widerlöv, Erik ; Bisette, Garth ; Nemeroff, Charles. / Reduced CSF neurotensin concentration in drug-free schizophrenic patients. In: Schizophrenia Research. 1988 ; Vol. 1, No. 1. pp. 55-59.
@article{b5d4b9207f62467eaa0faecdc9937c02,
title = "Reduced CSF neurotensin concentration in drug-free schizophrenic patients",
abstract = "The concentration of the tridecapeptide neurotensin was measured in CSF from 76 drug-free schizophrenic patients and 45 healthy controls. A highly significant difference was found between the two groups with lower concentration of neurotensin-like immunoreactivity in schizophrenic patients. Normalization of the lower concentrations was obtained in the same patients during ongoing neuroleptic treatment. The neurotensin concentrations in CSF was unrelated to sex, age, duration of the disorder or to previous neuroleptic treatment. Neurotensin levels did not differ between patients with or without a family history. A significant correlation was found between low neurotensin concentrations and decreased motor activity. No significant relationship was seen between the increment in CSF concentrations of neurotensin and clinical improvement during neuroleptic treatment. No significant correlation between CSF concentrations of neurotensin and HVA or 5-HIAA, major metabolites of dopamine and serotonin, respectively, could be demonstrated. However, in a limited number of the schizophrenic patients in this population, a significant correlation was seen between neurotensin and the noradrenaline metabolite MOPEG. The data support the hypothesis that certain schizophrenic patients may have a compromised CNS neurotensin system which might increase vulnerability for this disorder.",
keywords = "(Schizophrenia), Cerebrospinal fluid, Comprehensive Psychopathological Rating Scale, Monoamine, Neurotensin",
author = "Lindstr{\"o}m, {Leif H.} and Erik Widerl{\"o}v and Garth Bisette and Charles Nemeroff",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0920-9964(88)90040-0",
language = "English",
volume = "1",
pages = "55--59",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Reduced CSF neurotensin concentration in drug-free schizophrenic patients

AU - Lindström, Leif H.

AU - Widerlöv, Erik

AU - Bisette, Garth

AU - Nemeroff, Charles

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The concentration of the tridecapeptide neurotensin was measured in CSF from 76 drug-free schizophrenic patients and 45 healthy controls. A highly significant difference was found between the two groups with lower concentration of neurotensin-like immunoreactivity in schizophrenic patients. Normalization of the lower concentrations was obtained in the same patients during ongoing neuroleptic treatment. The neurotensin concentrations in CSF was unrelated to sex, age, duration of the disorder or to previous neuroleptic treatment. Neurotensin levels did not differ between patients with or without a family history. A significant correlation was found between low neurotensin concentrations and decreased motor activity. No significant relationship was seen between the increment in CSF concentrations of neurotensin and clinical improvement during neuroleptic treatment. No significant correlation between CSF concentrations of neurotensin and HVA or 5-HIAA, major metabolites of dopamine and serotonin, respectively, could be demonstrated. However, in a limited number of the schizophrenic patients in this population, a significant correlation was seen between neurotensin and the noradrenaline metabolite MOPEG. The data support the hypothesis that certain schizophrenic patients may have a compromised CNS neurotensin system which might increase vulnerability for this disorder.

AB - The concentration of the tridecapeptide neurotensin was measured in CSF from 76 drug-free schizophrenic patients and 45 healthy controls. A highly significant difference was found between the two groups with lower concentration of neurotensin-like immunoreactivity in schizophrenic patients. Normalization of the lower concentrations was obtained in the same patients during ongoing neuroleptic treatment. The neurotensin concentrations in CSF was unrelated to sex, age, duration of the disorder or to previous neuroleptic treatment. Neurotensin levels did not differ between patients with or without a family history. A significant correlation was found between low neurotensin concentrations and decreased motor activity. No significant relationship was seen between the increment in CSF concentrations of neurotensin and clinical improvement during neuroleptic treatment. No significant correlation between CSF concentrations of neurotensin and HVA or 5-HIAA, major metabolites of dopamine and serotonin, respectively, could be demonstrated. However, in a limited number of the schizophrenic patients in this population, a significant correlation was seen between neurotensin and the noradrenaline metabolite MOPEG. The data support the hypothesis that certain schizophrenic patients may have a compromised CNS neurotensin system which might increase vulnerability for this disorder.

KW - (Schizophrenia)

KW - Cerebrospinal fluid

KW - Comprehensive Psychopathological Rating Scale

KW - Monoamine

KW - Neurotensin

UR - http://www.scopus.com/inward/record.url?scp=0023908434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023908434&partnerID=8YFLogxK

U2 - 10.1016/0920-9964(88)90040-0

DO - 10.1016/0920-9964(88)90040-0

M3 - Article

C2 - 3154507

AN - SCOPUS:0023908434

VL - 1

SP - 55

EP - 59

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -